Clinical Trials Sponsored by Nippon Kayaku Co., Ltd.

Total 71 results

Nippon Kayaku Co., Ltd.

Completed

Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis

Lupus Nephritis

Germany, Czech Republic
Nippon Kayaku Co., Ltd.

Completed

A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

United States
Nippon Kayaku Co., Ltd.

Completed

Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer

Advanced Solid Tumors | Metastatic Triple Negative Breast Cancer

United States
Nippon Kayaku Co., Ltd.

Terminated

Efficacy and Safety of Deoxyspergualin in Renal Transplant Patient With Chronic Rejection

Chronic Rejection

Japan
Nippon Kayaku Co., Ltd.

Completed

A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer

Small Cell Lung Cancer

United States
Nippon Kayaku Co., Ltd.

Completed

Study of NK012 in Patients With Refractory Solid Tumors

Cancer

United States
Nippon Kayaku Co., Ltd.

Completed

Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis

Wegener's Granulomatosis

United Kingdom, Germany, Sweden, Czech Republic, Denmark, Netherlands
Nippon Kayaku Co., Ltd.

Completed

Study of NK012 and 5-FU/LV in Solid Tumors Followed by Dose Expansion in Colorectal Cancer

Metastatic Colorectal Cancer | Advanced Solid Tumors

United States
Nippon Kayaku Co., Ltd.

Completed

A Phase III Study of NK105 in Patients With Breast Cancer

Breast Cancer Nos Metastatic Recurrent

Japan
Celltrion
Nippon Kayaku Co., Ltd.

Completed

Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer

HER2-positive Carcinoma of Breast

Italy, South Africa, Mexico, Japan, Taiwan, Russian Federation, Philippines, Hungary, Romania, Spain, Bosnia and Herzegovina, India, Peru, Ukraine, Latvia, Argentina, Georgia, Belarus, Chile, France, Poland, Portugal
Nippon Kayaku Co., Ltd.
Handok Inc.

Terminated

Single Immediate Instillation of EO9 After TURBT in Patients With Non-muscle-invasive Bladder Cancer (NMIBC)

Bladder Cancer

Japan, Korea, Republic of
Nippon Kayaku Co., Ltd.
Shionogi; AEterna Zentaris

Completed

Clinical Pharmacological Study of GnRH Antagonist, Cetrorelix for Healthy Female Volunteer

Premenopause

Japan
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Extension Study of NS-089/NCNP-02 in DMD

Duchenne Muscular Dystrophy (DMD)

Japan
Hiroshima University
CHUGOKU KAYAKU CO., LTD.

Completed

Comparison of Absorbability Between Calcium Tablet and Calcium Ion Water

Healthy

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Phase 3 Study of SK-1403

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study of SK-1405 in Hemodialysis Patients With Uremic Pruritus

Uremic Pruritus in Hemodialysis Patients

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Trial of SK-1404 for Nocturia Due to Nocturnal Polyuria in Japanese Subjects

Nocturia Due to Nocturnal Polyuria

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion

Macular Degeneration | Macular Edema | Branch Retinal Vein Occlusion

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Phase II Dose-Finding Study of SK-0403 With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Effects of Miglitol on Daily Plasma Glucose in type2 Diabetes Treated With Insulin

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Bioavailability of [14C]-SK-1404 ADME & IV Microtracer Study

Nocturia

United Kingdom
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study to Investigate the Receptor Occupancy of SK-1405 in Healthy, Caucasian, Male Subjects

Pruritus

United Kingdom
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study to Evaluate Efficacy and Safety of Methacholine Chloride Challenge Test in Diagnosis of Adult Asthma

Asthma

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Open Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Double-Blind Study of Miglitol in Japanese With type2 Diabetes

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-SK-1405

Pruritus

United Kingdom
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema

Diabetic Macular Edema

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Double-Blind Trial of Miglitol in Type 2 Diabetic Patients With Insulin Treatment

Type 2 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Open Trial of Miglitol in Type 1 Diabetic Patients With Insulin Treatment

Type 1 Diabetes Mellitus

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout (UPWARD)

Diabetic Nephropathy

Japan
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Duchenne Muscular Dystrophy

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Korea, Republic of, Malaysia, Italy, Germany, Poland, United Kingdom, Thailand, Turkey
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis

Churg-Strauss Syndrome | Eosinophilic Granulomatosis With Polyangiitis

United States, Japan
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Active, not recruiting

Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Japan, China, United Kingdom, Netherlands, Spain, Norway, Russian Federation, Australia, Greece, Italy, New Zealand, Turkey, Mexico, Czechia, Canada
Nippon Medical School
Daiichi Sankyo Co., Ltd.

Active, not recruiting

STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study (STABLED)

Ischemic Stroke | Atrial Fibrillation Non-Rheumatic

Japan
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)

Duchenne Muscular Dystrophy

Korea, Republic of, Chile, Taiwan, China, United States, United Kingdom, Netherlands, Spain, Australia, Norway, Russian Federation, Greece, Italy, Turkey, Mexico, Canada, Hong Kong, New Zealand, Ukraine
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Not yet recruiting

NS-050/NCNP-03 in Boys With DMD (Meteor50)

Duchenne Muscular Dystrophy

United States
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Completed

Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)

Duchenne Muscular Dystrophy

Spain, United States, Russian Federation, Italy, China, Turkey
Nihon Pharmaceutical Co., Ltd

Completed

Study of NPF-08 in Patients Who Receive Colonoscopy

Patients Who Receive Colonoscopy

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase Ⅱ Dose Response Study of NPO-13 in Patients Undergoing Total Colonoscopy

Bowel Disease

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

Patients Undergoing Gastrointestinal Endoscopy

China
Nihon Pharmaceutical Co., Ltd

Completed

Phase I/II Clinical Trial of NPF-08 in Healthy Volunteers

Healthy Volunteers

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

Stevens-Johnson Syndrome | Toxic Epidermal Necrolysis

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Open-labeled Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

Gastric Cancer | Gastric Adenoma | Colon Nos Polypectomy Tubular Adenoma

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Study of NPO-11 in Patients Undergoing Therapeutic Upper Gastrointestinal Endoscopy

Gastric Cancer

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Exploratory Study of Additional Use of Scopolamine Butylbromide, Glucagon or NPO-11 Following Single Dose of NPO-11 in Healthy Adult Men

Healthy

Japan
Nihon Pharmaceutical Co., Ltd

Completed

Phase III Controlled Clinical Study of NPO-11 in Patients Undergoing Gastric Endoscopy

Patients Undergoing Gastric Endoscopy

Japan

Clinical Trials Sponsored by Nippon Kayaku Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations